Trial of Aciclovir Prophylaxis of Herpes Infections in Critical Care - TRAPHICC

Greater Glasgow Health Board (North Glasgow University Hospitals Division)0 个研究点目标入组 500 人开始时间: 2006年2月20日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•All patients (over 18 years) entering ICU provided
•1. Patient expected to stay in the ICU longer than 36 hours and with an endotracheal or tracheostomy tube inserted within 24 hours of admission to the ICU.
•2. Patient does not require treatment with Aciclovir, Valaciclovir, Ganciclovir, Foscarnet, Probenicid or other drug known to have anti herpes simplex activity
•3.Patient does not have a known allergy to Aciclovir.
•4.Females of childbearing age must have negative pregnancy test on admission
•5.Written informed consent from the patient or assent obtained from relatives.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•a)Duration of admission confidently expected to be less than 36 hours
•b)Patient has clinical features of HSV disease
•c)Patient previously randomised to this study.
•d)Patients deemed to be suitable for entry to another trial
•e)Previous hypersensitivity to aciclovir or Valaciclovir
•f)Patient requiring agent with anti herpes virus activity
•g)Patient previously enrolled in another trial of an investigational drug within the past 30 days
•h)Patient is pregnant or lactating
•j) Patient with endotracheal or tracheostomy in place for more than 24 hours before admission to ICU.

发起方

Greater Glasgow Health Board (North Glasgow University Hospitals Division)